Picard Medical closed at $7.19 on Nov 4, down 7.58%, 96.1% below its 52-week closing high. Volume of 31.9K shares was 0.07× its 20-day average (below normal).
Split-adjusted performance: -17.7% over one month, -38.0% over six months.
In the quarter ended Jun 30, 2026, revenue was $2.95M, with a net margin of -191.6%.
Short interest was 51.4K shares at the Oct 15 settlement, up 36.3% from the prior report (4.0% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 110 companies (100 = best)
Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| PMIPicard Medical | $7.19 | −7.58% | −38.0% | — | −191.6% | — | $16.8M | |
| RVPRetractable Technologies | $0.5660 | +0.71% | −18.3% | −31.1% | 38.5% | — | $16.9M | Compare |
| ARAYAccuray Incorporated | $0.1491 | +3.97% | −68.7% | −20.9% | −1.9% | — | $17.8M | Compare |
| MODDModular Medical | $1.67 | −5.65% | −57.3% | — | — | — | $15.9M | Compare |
| CTSOCytosorbents | $4.56 | +0.44% | −60.0% | +0.2% | −45.9% | — | $14.4M | Compare |
| PAVMPAVmed | $1.66 | −8.79% | −76.3% | +450.0% | −16603.0% | — | $13.3M | Compare |
| GUTSFractyl Health | $0.9725 | +8.27% | −89.0% | — | — | — | $12.9M | Compare |
| SINTSiNtx Technologies | $1.66 | −3.49% | −30.8% | +199.3% | −803.5% | — | $12.5M | Compare |
| FEMYFemasys | $1.44 | +2.86% | −84.1% | −18.9% | −1346.8% | — | $12.1M | Compare |
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing the SynCardia TAH, an implantable total artificial heart system. The company is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including the SynCardia TAH, which is designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. The SynCardia TAH replaces both the left and right ventricles as well as all four heart valves.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
